Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06789432 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy and Safety of Atorvastatin and Ezetimibe (10/10mg) Fixed Dose Combination Versus Atorvastatin (20mg) Monotherapy in Bangladeshi Population

StatusWithdrawn
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status changed: Recruiting → Withdrawn Sponsor's reason: Withdrawn by the sponsor before any participant was enrolled. Protocol-specified screening and randomization were not initiated at the study site. Not related to participant safety. Enrollment target: estimated 500 to confirmed 0 · Eligibility criteria shortened, about 19 words · Secondary endpoints: details revised at 3 of 7 entries · 1 more Show 4 more changesShow less
    • Enrollment target: estimated 500 to confirmed 0
    • Eligibility criteria shortened, about 19 words
    • Secondary endpoints: details revised at 3 of 7 entries
    • Site details revised
  2. Trial status: Not Yet Recruiting to Recruiting Primary completion date: Sep 2025 to Oct 2025 · Completion date: Sep 2025 to Dec 2025 · Site details revisedv3 Show 3 more changesShow less
    • Primary completion date: Sep 2025 to Oct 2025
    • Completion date: Sep 2025 to Dec 2025
    • Site details revised
  3. Secondary endpoints: 5 to 7 Site details revisedv2 Show 1 more changeShow less
    • Site details revised

    See this version in full on ClinicalTrials.gov ↗

  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is to evaluate the efficacy and safety of a fixed-dose combination of atorvastatin (10 mg) and ezetimibe (10 mg) compared to atorvastatin (20 mg) monotherapy in the Bangladeshi population. Researchers will compare atorvastatin (10 mg) and ezetimibe (10 mg) to atorvastatin (20 mg) monotherapy to see if atorvastatin (10 mg) and ezetimibe (10 mg) FDC works to treat dyslipidemia. Participants will: * Take a fixed-dose combination of atorvastatin (10 mg) and ezetimibe (10 mg) compared to atorvastatin (20 mg) monotherapy for 3 months * Follow-up visits at 6 weeks and 12 weeks for checkups and tests
Trial Details
NCT Number NCT06789432
Lead Sponsor Dr. Md. Alimur Reza
Conditions Hyperlipidemia (E.G., Hypercholesterolemia)
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov